Entera Funding: How Much Did They Raise & Key Investors

How Much Did Entera Raise?
Funding & Key Investors

Entera Bio has solidified its position in the biotechnology sector, securing a total of $7.5M in cumulative capital to advance its proprietary oral delivery platform. This recent strategic investment of $7.5M marks a pivotal milestone for the firm, providing the necessary liquidity to accelerate its clinical pipeline. By focusing on the transition from injectable to oral administration for complex proteins, the company is addressing significant inefficiencies in current therapeutic standards. This infusion of financing underscores investor confidence in the firm's ability to navigate the complex regulatory and clinical landscapes inherent in macromolecule development.

The capital allocation strategy reflects a commitment to scaling operations and advancing lead candidates through critical trial phases. As the company matures, this backing serves as a foundational element for its long-term growth trajectory, enabling the pursuit of high-impact medical solutions that target unmet needs in chronic disease management.

What is Entera?

Entera

Business Services

Research & Development

Manufacturing

Entera Bio operates at the intersection of pharmaceutical innovation and patient-centric drug delivery. The company specializes in the development of orally delivered macromolecules, specifically targeting peptides and therapeutic proteins that traditionally require injection. By engineering mini daily tablets, Entera Bio aims to transform the standard of care for patients suffering from conditions such as high-risk post-menopausal osteoporosis and hypoparathyroidism. Their lead product candidates, EB613 and EB612, represent a significant shift in therapeutic delivery, potentially increasing patient compliance and improving clinical outcomes. The firm's market position is defined by its unique ability to overcome the biological barriers of the gastrointestinal tract, a long-standing challenge in the biotechnology industry.

How much funding has Entera raised?

Entera has raised a total of $282.5M across 1 funding round:

2016

Debt

$7.5M

Debt (2016): $7.5M with participation from Pontifax

Key Investors in Entera

Pontifax

Pontifax Venture Capital specializes in groundbreaking innovations in life sciences, focusing on transformative healthcare technologies across all development stages. The firm provides hands-on guidance and strategic expertise to clinical-stage companies, leveraging its experience in capital markets and mergers and acquisitions to foster growth.

What's next for Entera?

Looking ahead, Entera Bio is positioned to leverage its recent capital injection to drive its clinical programs toward regulatory milestones. The strategic focus remains on the successful execution of clinical trials for EB613 and EB612, which are essential for validating the efficacy and safety of their oral delivery technology. As the company progresses, it will likely seek to expand its pipeline through internal research or strategic partnerships, further diversifying its therapeutic portfolio. The firm's ability to maintain its technological edge in the competitive landscape of peptide therapeutics will be a key determinant of its future valuation and market influence. Investors will be closely monitoring the data readouts from ongoing studies as indicators of the platform's scalability and commercial viability.

See full Entera company page

See More Financial Insights